Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Quest Diagnostics, Inc.
Nieuws
Quest Diagnostics, Inc.
DGX
NYS
: DGX
| ISIN: US74834L1008
16/09/2025
180,16 USD
(-0,25%)
(-0,25%)
16/09/2025
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
16 september 2025 ·
Quest Diagnostics to Speak at the Jefferies Healthcare Services Conference
· Persbericht
4 september 2025 ·
Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering
· Persbericht
2 september 2025 ·
Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index
· Persbericht
26 augustus 2025 ·
Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan
· Persbericht
25 augustus 2025 ·
FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics
· Persbericht
16 augustus 2025 ·
Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference
· Persbericht
14 augustus 2025 ·
Quest Diagnostics Declares Quarterly Cash Dividend
· Persbericht
7 augustus 2025 ·
Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types
· Persbericht
5 augustus 2025 ·
Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care
· Persbericht
29 juli 2025 ·
Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing
· Persbericht
22 juli 2025 ·
Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
· Persbericht
15 juli 2025 ·
Quest Diagnostics Introduces Testing for Oropouche Virus
· Persbericht
9 juli 2025 ·
Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease
· Persbericht
25 juni 2025 ·
Quest Diagnostics Releases 2024 Corporate Responsibility Report
· Persbericht
23 juni 2025 ·
Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025
· Persbericht
10 juni 2025 ·
Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology
· Persbericht
20 mei 2025 ·
More Americans Know Their Streaming Platform Passwords by Heart Than Their Cholesterol Score, New Survey Reveals
· Persbericht
16 mei 2025 ·
Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference
· Persbericht
15 mei 2025 ·
Quest Diagnostics Declares Quarterly Cash Dividend
· Persbericht
13 mei 2025 ·
Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe